41 Prevalence of secondary prevention medication use in South America 2 47. Pantoni F, Caruso R, Mezzalira D, Arena R, Amaral-Neto O. Continuous Positive Airway Pressure During Exercise Improves Walking Time in Patients Undergoing Inpatient Cardiac Rehabilitation After Coronary Artery Bypass Graft Surgery. J Cardiopulm Rehabil Prev. 2016;36:20–7. 48. Birk MG, Carvalho Goulart A, Lotufo PA, Martins Benseñor I. Secondary prevention of coronary heart disease : a cross-sectional analysis on the Brazilian Longitudinal Study of Adult Health ( ELSA-Brasil ). Sao Paulo Med J. 2019;137(3):223–33. 49. Lorenzo A De, Oliveira G, Naue VM, Lima RSL. Influence of typical angina versus inducible myocardial ischemia in the contemporary management of stable coronary artery disease. Ther Adv Cardiovasc Dis. 2014;8(4):145–54. 50. Bohatch Júnior MS, Matkovski PD, Di Giovanni FJ, Fenili R, Varella EL, Dietrich A. Incidence of postoperative atrial fibrillation in patients undergoing on-pump and off-pump coronary artery bypass grafting. Braz J Cardiovasc Srug. 2015;30(3):316–24. 51. Feguri GR, Ruiz P, Lima L De, Borges DDC, Toledo LR. Preoperative carbohydrate load and intraoperatively infused omega-3 polyunsaturated fatty acids positively impact nosocomial morbidity after coronary artery bypass grafting : a double- blind controlled randomized trial. Nutr J. 2017;16(24):1–7. 52. Garlet AB, Machado Cardoso D, Daros dos Santos T, Nunes Pereira S. Relationship between functional class and left ventricular ejection fraction in patients with coronary heart disease candidates for cardiac rehabilitation. Sci Med. 2017;27(3). 53. Lelis JD, Chaves G, Lima G, Ghisi DM, Grace SL, Britto RR. Validity of the Incremental Shuttle Walk Test to Assess Exercise Safety When Initiating Cardiac Rehabilitation in Low-Resource Settings. J Cardiopulm Rehabil Prev. 2019;99(April 2017):E1–7. 54. Alexandre A, Aguiar F De, Mourilhe-rocha R, Esporcatte R, Amorim LC. Original Article Long-Term Analysis in Acute Coronary Syndrome : are there any Differences in Morbidity and Mortality ? 2010;705–12. 55. Weber R, Fernandes A, Dantas JM, Oliveira DC, Bezerra HG, Sandoli F, et al. Original Article Impact of Stenting and Oral Sirolimus on Endothelium-Dependent and Independent Coronary Vasomotion. 2011;290–9. 56. Fuchs ARCN, Meneghelo RS, Stefanini E, Paola AV De, Smanio PEP, Cardiovascular DR, et al. Exercise may cause myocardial ischemia at the anaerobic threshold in cardiac rehabilitation programs. 2009;42:272–8. 57. Abreu-Silva EO, Costa RA, Abizaid AS, Perin M, Cardoso RF, Prudente ML, et al. Stents Farmacológicos Liberadores de Everolimus XienceTM V no Tratamento de Pacientes com Lesões Coronárias Complexas na Prática Diária: Resultados Iniciais do Registro Brasileiro BRAVO. Rev Bras Cardiol Invasiva. 2011;19(4):357–66. 58. Baptista VC, Palhares LC, Paulo P, Oliveira M De, Mota L, Filho S, et al. Six-minute walk test as a tool for assessing the quality of life in patients undergoing coronary artery bypass grafting surgery. 2012;27(2):231–9. 59. Rossi E, Perman G, Michelangelo H, Alonzo CB, Brescacin L, Kopitowski KS, et al. Adherencia a la prevención secundaria de la enfermedad coronaria. Med (Buenos Aires). 2014;74:99–103. 60. Trivi M, Lakowsky A, Zeballos C, Duronto E, Márquez LL, Rapallo C, et al. Registro prospectivo de tratamiento antitrombótico en síndromes coronarios agudos ( EPICOR ) Prospective Registry of Antithrombotic Therapy in Acute Coronary Syndromes ( EPICOR ). Rev Argent Cardiol. 2019;87(1). 61. Siniawski D, Masson W, Rossi E, Damonte J, Halsband A, Pizarro R. Elegibilidad para la indicación de inhibidores de PCSK9 según las recomendaciones de diferentes sociedades científicas. Med. 2019;79(2):104–10. 62. Alvarez J, Migliaro G, Leiva G, Fernández-recalde ML, Donato B, Baglioni P, et al. Angioplastia primaria en diabéticos vs . no diabéticos con infarto agudo de miocardio : predictores de mortalidad. Rev Gastroenterol México. 2016;86(1):11– 7. 63. Gurfinkel EP, Leon R, Fuente D, Mendiz O. Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions ( FLUVACS ) Study One-year follow-up. Eur Heart J. 2004;25:25–31. 64. Castillo Costa YB, Mauro VM, Charask AA, Fairman E, Buhezo H, Barrero C. Use of high-intensity statin strategy. Are the guidelines followed? Rev Argent Cardiol. 2018;86(1):45–7. 65. Stockins B, Albornoz F, Martínez D, Campos P, Gajardo J, Lamich R, et al. Resultados chilenos del registro intenacional de factores de riesgo y tratamiento de angina inestable e infarto al miocardio sin supradesnivel del segmento ST: ACCORD (ACcute CORonary syndrome Descriptive study). Rev Med Chile. 2011;139:19–26. 66. Nazzal A, Mercadal E, Garcés E, Yovaniniz P, Sanhueza P. Prevención secundaria post infarto agudo de miocardio en hospitales públicos: implementación y resultados de las garantías GES. Rev Med Chile. 2013;141:977–86. 67. Neira V V, Potthoff MN, Quiñiñir LS, Lopez GR, Stockins BF, Castillo CB, et al. Logro de metas de prevención secundaria, prescripción farmacológica y eventos cardiovasculares mayores en pacientes con enfermedad coronaria. Rev Med Chile. 2013;141:870–8. 68. Noriega V, Pennanen C, Sánchez MP, Chiong M, Llancaqueo M, Lavandero S, et al. (TTA)n Polymorphism in 3-Hydroxy3-Methylglutaryl-Coenzyme A and Response to Atorvastatin in Coronary Artery Disease Patients. Basic Clin Pharmacol Toxicol. 2008;(104):211–5.
RkJQdWJsaXNoZXIy MTk4NDMw